AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20045151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 52
Study 18779236 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 322
Study 18779236 — intervention group
Group type: COMPARATOR
Intervention: Control group (home monitoring with a blood glucose meter)
Number of subjects: 322
Study 18779236 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucose monitoring and Control group
Number of subjects: 322
Study 15966877 — intervention group
Group type: EXPERIMENTAL
Intervention: BDX Coll + GTR
Number of subjects: 32
Study 15966877 — intervention group
Group type: COMPARATOR
Intervention: Access flap surgery
Number of subjects: 32
Study 12202120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid (20mg hyaluronic acid/2ml Hyalart) administered via five injections (one injection per week)
Number of subjects: 43
Study 10353368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsolateral prefrontal lesions
Number of subjects: 0
Study 10353368 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 10353368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal lesions
Number of subjects: 0
Study 7813259 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP score (PCPSc) assessed on treatment days D0, D3, D7, D14, and D21
Number of subjects: 78
Study 7813259 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH levels during treatment
Number of subjects: 78
Study 7813259 — intervention group
Group type: EXPERIMENTAL
Intervention: PaO2 at hospital admission
Number of subjects: 78
Study 2007104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 20
Study 2007104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine
Number of subjects: 20
Study 6386634 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzym-Paractol
Number of subjects: 50
Study 6386634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30887607 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg
Number of subjects: 2000
Study 30887607 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 2000
Study 30355364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 134
Study 30355364 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure
Number of subjects: 134
Study 25302581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (futhan)
Number of subjects: 73
Study 25302581 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 73
Study 22706414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimebon add-on treatment
Number of subjects: 56
Study 22706414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20050336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin plus rifampicin (1 g intravenous every 12 hrs plus 300 mg twice daily by mouth)
Number of subjects: 93
Study 20050336 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin only
Number of subjects: 93
Study 20050336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin plus rifampicin
Number of subjects: 93
Study 17296974 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblimersen (3 mg/kg/d as a 7-day continuous intravenous infusion) plus fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) for 3 days, for up to six cycles.
Number of subjects: 241
Study 17296974 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) for 3 days (chemotherapy-only group).
Number of subjects: 241
Study 17950856 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta every 2 weeks
Number of subjects: 447
Study 17950856 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta every 4 weeks
Number of subjects: 447
Study 17950856 — intervention group
Group type: COMPARATOR
Intervention: Epoetin treatment (control)
Number of subjects: 447
Study 17950856 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (methoxy polyethylene glycol-epoetin beta and epoetin)
Number of subjects: 447
Study 15572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day) combined with ongoing lithium or valproate
Number of subjects: 85
Study 15572737 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with ongoing lithium or valproate
Number of subjects: 85
Study 15572737 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine co-therapy
Number of subjects: 85
Study 11153292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10.5 mg subcutaneously at the end of surgery followed by a subcutaneous infusion of 1.75 mg/h for 24 to 36 hours
Number of subjects: 72
Study 11153292 — intervention group
Group type: COMPARATOR
Intervention: Saline (equivalent volume)
Number of subjects: 72
Study 11153292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 72
Study 11153292 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac and Saline
Number of subjects: 72
Study 9185028 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin phenotype allele 1
Number of subjects: 39
Study 9185028 — intervention group
Group type: COMPARATOR
Intervention: Haptoglobin phenotype allele 2
Number of subjects: 39
Study 1585039 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning bowel training group
Number of subjects: 46
Study 1585039 — intervention group
Group type: COMPARATOR
Intervention: Scheduled suppository use
Number of subjects: 46
Study 1585039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel training group coinciding with previous pattern
Number of subjects: 46
Study 1585039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel training group conflicting with previous pattern
Number of subjects: 46
Study 3895405 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypure
Number of subjects: 18
Study 3895405 — intervention group
Group type: COMPARATOR
Intervention: Varidase
Number of subjects: 18
Study 30782236 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mental health and disaster preparedness intervention
Number of subjects: 480
Study 30008080 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated instructions on tablets
Number of subjects: 12841
Study 30008080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training
Number of subjects: 12841
Study 30008080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training in Hospital 1
Number of subjects: 12841
Study 30008080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training in Hospital 2
Number of subjects: 12841
Study 27090301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (single sub-anesthetic dose)
Number of subjects: 0
Study 27090301 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 25650044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume CVVH (4000 mL/h)
Number of subjects: 28
Study 25650044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume CVVH (2000 mL/h)
Number of subjects: 28
Study 25650044 — intervention group
Group type: COMPARATOR
Intervention: Control group (abdominal infection)
Number of subjects: 28
Study 25650044 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (before treatment)
Number of subjects: 28
Study 25650044 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (after treatment)
Number of subjects: 28
Study 23971855 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy with ultrasonic dissection (MC)
Number of subjects: 88
Study 23971855 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 88
Study 22044553 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated home visit package delivered by community health workers, including two antenatal visits, a postnatal visit within 48 hours of birth, and four additional visits during the first two months of the infant's life.
Number of subjects: 120
Study 22044553 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 120
Study 18852183 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering treatment (including angiotensin-converting enzyme inhibitors, calcium antagonists, angiotensin receptor blockers, diuretics/beta-blockers)
Number of subjects: 190617
Study 16582060 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 327
Study 16582060 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 327
Study 16582060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 327
Study 16582060 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 327
Study 14578545 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention interventions (specific details not provided)
Number of subjects: 0
Study 14578545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of HIV prevention interventions (specific details not provided)
Number of subjects: 0
Study 10732745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine cycles of dose-escalated FEC (fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 36
Study 10732745 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of FEC followed by high-dose chemotherapy with alkylating agents (CTCb)
Number of subjects: 36
Study 10732745 — intervention group
Group type: COMPARATOR
Intervention: Six cycles of standard intravenous CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 36
Study 9004446 — intervention group
Group type: EXPERIMENTAL
Intervention: Three dose pre-exposure series (days 0, 7, and 28) followed by one booster dose (day 360)
Number of subjects: 0
Study 9004446 — intervention group
Group type: EXPERIMENTAL
Intervention: Five dose simulated post-exposure series (days 0, 3, 7, 14, and 28)
Number of subjects: 0
Study 9004446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyssavac‐HDC vaccine
Number of subjects: 0
Study 1547049 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 1 mg
Number of subjects: 30
Study 1547049 — intervention group
Group type: COMPARATOR
Intervention: propranolol 1 mg
Number of subjects: 30
Study 3890601 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol inhalation powder
Number of subjects: 20
Study 3890601 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol MDI
Number of subjects: 20
Study 31248471 — intervention group
Group type: EXPERIMENTAL
Intervention: GSP301 (olopatadine 665 μg and mometasone 25 μg)
Number of subjects: 601
Study 31248471 — intervention group
Group type: COMPARATOR
Intervention: Placebo pH 3.7
Number of subjects: 601
Study 31248471 — intervention group
Group type: COMPARATOR
Intervention: Placebo 7.0
Number of subjects: 601
Study 29235162 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg, thrice daily for 12 weeks)
Number of subjects: 82
Study 26928828 — intervention group
Group type: EXPERIMENTAL
Intervention: Free malaria rapid diagnostic test (RDT) offered to 37.6% of patients
Number of subjects: 1525
Study 26928828 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients feeling relatively healthy by the second day of treatment
Number of subjects: 1525
Study 24488335 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 66
Study 22682063 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) group
Number of subjects: 100
Study 22682063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (strength training and walking program)
Number of subjects: 100
Study 17437727 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline platelet count >= 234 x 10(9)/L
Number of subjects: 2021
Study 17437727 — intervention group
Group type: COMPARATOR
Intervention: Baseline platelet count < 234 x 10(9)/L
Number of subjects: 2021
Study 17437727 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline platelet count
Number of subjects: 2021
Study 17437727 — intervention group
Group type: COMPARATOR
Intervention: Lower baseline platelet count
Number of subjects: 2021
Study 17437727 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count quartiles
Number of subjects: 2021
Study 15126550 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Testosterone Undecanoate (TU)
Number of subjects: 30
Study 15126550 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Testosterone Undecanoate (TU) plus 150 mg Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 30
Study 15126550 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Testosterone Undecanoate (TU) plus 300 mg Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 30
Study 15126550 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline period)
Number of subjects: 30
Study 11377113 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled RCT
Number of subjects: 0
Study 11377113 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented methodological stringency
Number of subjects: 0
Study 9458602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bass appliance treatment for 6 months
Number of subjects: 47
Study 9458602 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 47
Study 7962682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (7 mg)
Number of subjects: 12
Study 7962682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (14 mg)
Number of subjects: 12
Study 7962682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7962682 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery night after active nicotine patch
Number of subjects: 12
Study 3619425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone 1 g
Number of subjects: 20
Study 3619425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone 2 g
Number of subjects: 20
Study 31742615 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Vitamin D Supplementation (10,000 IU)
Number of subjects: 0
Study 31742615 — intervention group
Group type: COMPARATOR
Intervention: Low-Dose Vitamin D Supplementation (400 IU)
Number of subjects: 0
Study 28960888 — intervention group
Group type: COMPARATOR
Intervention: Naldemedine (0.1-100 mg)
Number of subjects: 69
Study 28960888 — intervention group
Group type: COMPARATOR
Intervention: Naldemedine (3-30 mg once daily for 10 days)
Number of subjects: 69
Study 28960888 — intervention group
Group type: COMPARATOR
Intervention: Naldemedine
Number of subjects: 69
Study 28960888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 26537155 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg nicotine gum
Number of subjects: 24
Study 26537155 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg moclobemide
Number of subjects: 24
Study 26537155 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 6 mg nicotine gum and 75 mg moclobemide
Number of subjects: 24
Study 24243529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 24243529 — intervention group
Group type: COMPARATOR
Intervention: No dapagliflozin (Control)
Number of subjects: 0
Study 22914208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% estriol vaginal gel (50 μg per application, 1 g daily for 3 weeks, then twice weekly up to 12 weeks)
Number of subjects: 167
Study 22914208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% estriol vaginal gel
Number of subjects: 167
Study 22914208 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 167
Study 19732072 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate during the 6-month open-label phase
Number of subjects: 811
Study 19732072 — intervention group
Group type: COMPARATOR
Intervention: Topiramate during the 6-month double-blind phase
Number of subjects: 811
Study 17395395 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA) 2.5 mg for 1 month and 5 mg for 2 months
Number of subjects: 20
Study 17395395 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 17395395 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA)
Number of subjects: 20
Study 15761420 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/wk
Number of subjects: 498
Study 15761420 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 2 mg/kg/wk
Number of subjects: 498
Study 15761420 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (1 or 2 mg/kg)
Number of subjects: 498
Study 12084137 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP)
Number of subjects: 131
Study 12084137 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 131
Study 10561135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (MAP) goal of 92 mm Hg or less (group I)
Number of subjects: 129
Study 10561135 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial blood pressure (MAP) goal of 100 to 107 mm Hg (group II)
Number of subjects: 129
Study 10561135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 129
Study 8703598 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with lingual flap retraction
Number of subjects: 771
Study 8703598 — intervention group
Group type: COMPARATOR
Intervention: Surgery without lingual flap retraction
Number of subjects: 771
Study 1924658 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 17
Study 6287838 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (20 g/day)
Number of subjects: 10
Study 6287838 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn bran (20 g/day)
Number of subjects: 10
Study 30343489 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone‐based symptom and side effect monitoring with physician feedback over 6 months
Number of subjects: 1270
Study 30343489 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus three non‐interactive diabetes educational calls
Number of subjects: 1270
Study 28345425 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diclofenac/3% menthol gel (n=117)
Number of subjects: 385
Study 28345425 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% diclofenac (n=112)
Number of subjects: 385
Study 28345425 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% menthol (n=77)
Number of subjects: 385
Study 28345425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=75)
Number of subjects: 385
Study 25391601 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventionist-led (IL) group
Number of subjects: 99
Study 25391601 — intervention group
Group type: COMPARATOR
Intervention: Self-guided (SG) group
Number of subjects: 99
Study 25117129 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 98792
Study 22567095 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 149
Study 22567095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 19079812 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial switch operation with deep hypothermia and predominantly total circulatory arrest
Number of subjects: 155
Study 19079812 — intervention group
Group type: COMPARATOR
Intervention: Arterial switch operation with predominantly low-flow continuous cardiopulmonary bypass
Number of subjects: 155
Study 19079812 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative seizures
Number of subjects: 155
Study 19079812 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with academic problems at age 8
Number of subjects: 155
Study 17314119 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (placebo group)
Number of subjects: 2546
Study 15099140 — intervention group
Group type: EXPERIMENTAL
Intervention: Local confidence
Number of subjects: 0
Study 15099140 — intervention group
Group type: EXPERIMENTAL
Intervention: Global confidence
Number of subjects: 0
Study 15099140 — intervention group
Group type: EXPERIMENTAL
Intervention: Informing participants about normative status of estimates below 50%
Number of subjects: 0
Study 10843263 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural verbalization
Number of subjects: 60
Study 10843263 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative verbalization
Number of subjects: 60
Study 10843263 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 60
Study 9324620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrafusin 10% (10 ml/kg BW/24 h of 10% amino acid solution)
Number of subjects: 30
Study 9324620 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosteril 10% (10 ml/kg BW/24 h of 10% amino acid solution)
Number of subjects: 30
Study 9324620 — intervention group
Group type: COMPARATOR
Intervention: Isotonic electrolyte solution (Jonosteril, control group) (10 ml/kg BW/24 h)
Number of subjects: 30
Study 9324620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrafusin 10%
Number of subjects: 30
Study 7968327 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (0.3 microgram/kg intravenous infusion one hour after cardiopulmonary bypass)
Number of subjects: 48
Study 7968327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3884697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg parenterally
Number of subjects: 13
Study 3884697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg orally
Number of subjects: 13
Study 3884697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3884697 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-labeled metoclopramide
Number of subjects: 13
Study 3371390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR 100 mg
Number of subjects: 10
Study 3371390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR 200 mg
Number of subjects: 10
Study 3371390 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 10
Study 3371390 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 10
Study 3371390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10